Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGT-PD
- Development stage
- Preclinical
- Lead developer
- Bloomsbury Genetic Therapies
- Modality
- Gene Therapies
- Administration
- Intracerebral
01
Overview
BGT-PD is an investigational adeno-associated virus serotype 2 (AAV2) gene therapy being developed by Bloomsbury Genetic Therapies for the treatment of Parkinson's disease. The therapy is designed to deliver a functional copy of the *SLC6A3* gene, which encodes the dopamine transporter (DAT), directly into the brain. By restoring DAT expression and function, BGT-PD aims to improve the regulation of synaptic dopamine levels, potentially providing a more stable therapeutic effect and reducing the motor fluctuations associated with standard oral levodopa treatment. The program is currently in the preclinical stage of development.
02
Targets
DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on BGT-PD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGT-PD.